Table 1.
Baseline Characteristics for Methotrexate Sodium– and Adalimumab-Treated Patientsa
| Characteristic | Study Treatment | P Value | |
|---|---|---|---|
| Methotrexate (n = 15) |
Adalimumab (n = 15) |
||
| Male sex | 13 | 11 | .36 |
| Age, mean (range), y | 50.3 (22–69) | 50.5 (22–69) | .97 |
| Race, white | 14 | 12 | .28 |
| Mean PASIb | 15.9 | 16.8 | .79 |
| Target lesion location | |||
| Upper extremity | 3 | 3 | .98 |
| Lower extremity | 6 | 5 | |
| Trunk | 5 | 6 | |
| Buttock | 1 | 1 | |
| History of psoriatic arthritis | 3 | 2 | .62 |
| Previous systemic therapy | 4 | 6 | .44 |
| Mean BMI | 35.0 | 32.1 | .62 |
| Disease duration, mean (range), y | 21.5 (0–47) | 17.3 (1–45) | .41 |
| Age at onset, mean (range), y | 29.1 (5–68) | 33.3 (4–56) | .54 |
Abbreviations: BMI, body mass index (calculated as weight in kilograms divided by height in meters squared); PASI, Psoriasis Area Severity Index.
a
Unless otherwise indicated, data are expressed as number of patients.
b
Values range from 0 (no disease) to 72 (severe disease).